 |
|
 |
      
|
Studies for Normal Volunteers and Alzheimer's Disease Patients Enrolling Trials for Normal Volunteers ADCS Instrument Trial for Normal Subjects: Normal elderly volunteers will be evaluated once a year for four years as part of a study to improve the design and efficiency of future primary prevention trials for Alzheimer’s disease. Participants will receive feedback about their cognitive status and will also be eligible for free books about aging and memory. Reimbursement for time and effort will be provided. More Information
about this study Upcoming Trials for Alzheimer’s Disease (AD) Galantamine
for AD: Patients
with mild to moderate Alzheimer’s disease will have the opportunity
to participate in this study which will test the relative benefits of
galantamine and aricept. Subjects will receive either of the two drugs
for at least 10 weeks and for as long as 32 weeks. Diagnostic and memory
evaluations will be done during that time. Sleeping patterns will also
be monitored for 3 separate weeks during the study using a wristwatch-like
device that records movements.
Aricept
for AD: Mild to moderate Alzheimer’s disease
patients will have another opportunity to participate in a trial which
will study the effects of maintaining Aricept treatment as compared
to switching to Galantamine therapy. Subjects will receive either of
the two drugs for 12 weeks and visits will be about every other week.
Patients must be on Aricept for 3 months prior to being involved in
the study. Those who complete the program will receive aricept for 3
months. For more information about these pharmaceutical studies, call the Clinical Trials Coordinator, at (212) 263-5708. |
|
About
the ADRC | For Patients & Families
| For Professionals | Programs
& Services
|
|
 Silberstein Aging & Dementia Research Center New York University School of Medicine © 2002 New York University Ethics and Disclaimer |
  |
 |
 |
 |
